After successfully selling three small molecule manufacturing plants around the world, Roche was unable to find a buyer for a site in Clarecastle, Ireland. Now, it’s set to close up there and lay off 132 workers by next year, The Irish Times reports.
Roche is already in the process of a phased exit, and the drugmaker expects the process to conclude by March 2020, the newspaper reports. The company has set aside €24 million for the employees who are still working at the site, the newspaper reports, citing Roche Ireland documents. That means each worker could be in line for a €180,000 termination payment.
In 2015, Roche unveiled a massive shift of manufacturing priorities, setting out to downsize its small molecule manufacturing capacity and bolster its biologics presence. Before that, the drugmaker announced it’d spend €800 million to expand biologics capacity at sites in Germany, Switzerland and the U.S.
As part of the moves, Roche said it would cut 1,200 jobs and exit four small molecule sites around the world. Roche ultimately found buyers for its plants in the U.S., Italy and Spain, but couldn’t sell the Ireland site, and now it’s closing up shop.
The drugmaker sold its site in Spain to Recipharm, which won a long-term deal to supply Roche with solid-dose drugs and agreed to keep 200 workers at the facility. Roche used similar contract language to sell its other plants.
Roche’s bet on biologics has been paying off as the company holds a leadership position in cancer and other diseases. But it’ll face a new test as biosimilars to its three top cancer drugs hit the U.S. market, threatening $10 billion in sales. Roche executives believe the company’s newer medicines can fill the gap created by biosimilars and add some growth.
By Eric Sagonowsky
Source: Fierce Pharma
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.